Human-led Intelligence
for real life systems.
SymbAIo builds adaptive intelligence for the moments that matter most — chronic illness, survival, safety, and the complex human experiences that current technology ignores.
Founder featured in
Oprah / OWN NetworkGrey’s Anatomy / ABC"The most powerful intelligence isn't artificial.
It's symbiotic."
We believe the future of AI isn't about replacing human judgment — it's about building systems intelligent enough to understand the full complexity of human experience and humble enough to support it.
Where Intelligence Meets Unmet Need
SymbAIo operates at the intersection of the most consequential technological shift in human history and the most complex unmet needs humans face. We build behavioral intelligence systems that read pattern across three dimensions: biological signals, human safety, and the systems people navigate every day. The global AI market is projected to exceed $4.2 trillion by 2035. The wearable medical device market will surpass $500B by 2035. AI in healthcare will exceed $500B by 2033. And globally, 840 million women have experienced intimate partner or sexual violence — at a cost the EU alone estimates at €366B (~$423B USD) per year. No platform connects these realities into a single intelligence layer that keeps the individual in control. That's the gap. That's SymbAIo.
$4.2T+
Global AI Market by 2035
27.7%
Annual AI Market Growth Rate, 2025–2030
$500B+
Wearable Medical Devices by 2035
$500B+
AI in Healthcare by 2033
840M
Women who have experienced partner or sexual violence globally (WHO, 2025)
€366B (~$423B USD)/yr
Annual cost of gender-based violence in the EU alone
Sources: Precedence Research, Statista, Grand View Research, WHO (2025), UN Women
A Super Integration
Platform
SymbAIo uses biomarkers from wearables to create a traceable, correlative blueprint for the user. We analyze, index, track, and recognize patterns from your data — helping you identify what works for you.
Think of it as the intelligence layer between your lived experience and the systems designed to serve you — except this time, the system actually listens.
View Signature SuiteOne Platform. Built in Layers.
iMpatient™ is our flagship — launching May 30, 2026. K@te™ follows in November 2026. mønk™ is the proprietary intelligence engine powering both. Together, they form the foundation for an ecosystem built to expand into signal processing and cognitive wellness. The AI infrastructure beneath mønk™ runs on Claude by Anthropic — aligned with our commitment to human safety, interpretability, and sovereignty.
iMpatient™
Your health. Your signal. Your sovereignty
A patient-first health intelligence platform that transforms wearable biomarker data into traceable, correlative blueprints. Launching May 30, 2026
K@te™
Awareness before crisis
A contextual safety companion for survivors of psychological violence, coercive control, and people navigating unsafe environments. K@te™ reads what your body already knows — using biomarker signals, behavioral patterns, and environmental context to surface awareness before crisis. Not surveillance. Sovereignty. Launching November 2026
mønk™
The quiet architecture beneath
The foundational operating layer that powers the entire Signature Suite. Privacy-first, non-reductive intelligence architecture. Currently in BETA, powering test versions of iMpatient™ and K@te™
iMpulSIM™
Signals before they become noise
A signal processing engine that identifies meaningful patterns in complex data streams before they become actionable crises. Early warning, not late reaction
On the Horizon
NeuroSPARK™ — Cognitive wellness mapping at the intersection of mental load, biological signals, and environmental context. Currently in concept phase.
Integrates With
Your Devices. Your Data. Your Intelligence.
iMpatient™ connects to the wearables and health platforms you already use — pulling biomarker data into a single, correlative intelligence layer you control.
iMpatient™ integrates with leading wearable and health platforms at launch
How SymbAIo Becomes a Business
SymbAIo is building a platform business with multiple revenue pathways, anchored by iMpatient™ as the first product to market.
Phase 1 — 2026
Direct-to-Consumer
iMpatient™ launches May 30, 2026 as a freemium health intelligence app. Free tier: basic biomarker tracking. Premium tier ($14.99/month): full correlative blueprints, longitudinal health narratives, and provider-ready insight summaries. K@te™ follows in mid-November 2026 — a contextual safety companion for survivors of psychological violence and coercive control, expanding SymbAIo's platform into the survivor safety space.
Phase 2 — 2027–2028
B2B Health System Licensing
Licensed integrations with health systems, telehealth platforms, and employer wellness programs. Per-seat SaaS model for institutional access to de-identified, patient-consented intelligence
Phase 3 — 2028+
Platform & Ecosystem
As the Signature Suite scales, mønk™ becomes the licensable intelligence layer — a privacy-first data orchestration platform for third-party developers building on human-context data
Born from
Lived Experience
Azure Antoinette
Founder & CEO
SymbAIo was founded by Azure Antoinette — a commissioned poet, TED Speaker, GRAMMY™ Considered artist, and self-taught developer named the "Maya Angelou of the Millennial Generation" by Forbes. A nearly 20-year survivor of Multiple Sclerosis, Azure spent over a decade navigating a healthcare system that wasn't designed to listen to patients like her.
That experience didn't just inspire a company. It revealed a fundamental gap in how technology understands human complexity. Today, she is channeling two decades of advocacy, storytelling expertise, and personal resilience into building the future of patient-centered care.
As the creator of iMpatient™ — powered by mønk™, a patent-pending pattern recognition engine — Azure is architecting the behavioral intelligence platform she needed but never had. SymbAIo exists to close the gap between what technology assumes and what humans actually need.
Trusted Across Industries
Building across pharma, technology, community, law, and media.
Pre-Seed. Open Round.
SymbAIo is raising a $3.2M pre-seed round at a $25M valuation to bring iMpatient™ to market and scale the mønk™ platform layer.
$1.2M committed. Round actively closing.
Use of Funds
Full investment disclosure, data room access, and company documentation available upon request.